Bagri Puneet Kumar, Singh Daleep, Singhal Mukesh Kumar, Singh Guman, Mathur Gaurav, Jakhar Shankar Lal, Beniwal Surender, Sharma Neeti, Kumar Harvindra Singh, Sharma Ajay, Bardia Megh Raj
Dept. of Radiation Oncology; Acharya Tulsi Regional Cancer Treatment & Research Institute, Bikaner-334003, Rajasthan, India.
Dept. of Medicine; PBM hospital, Bikaner-334003, Rajasthan, India.
Iran J Cancer Prev. 2014 Spring;7(2):66-72.
Patients which have diagnosed with a cancer, have a life time risk for developing another de novo malignancy depending on various inherited, environmental and iatrogenic risk factors. Cancer victims could survive longer due to settling treatment modalities, and then would likely develop a new metachronous malignancy.This article aims to report our observed trend of increasing, in prevalence of both synchronous and metachronous second primary malignancy, among the cancer victims, and to review the relevant literature.
A hospital based retrospective gathering of prospective data, among the patients that have diagnosed with second de novo malignancy.The study has conducted over a 4 years period from 2009 to 2012. All patients that have diagnosed with a histologically proven second malignancy as per Warren and Gates criteria have included. Various details which have regarded site, age at presentation, sex, synchronous or metachronous, treatment have recorded.
Among 41 cases of multiple primary malignancies that have observed, 8 were synchronous (19.51%) and 33 were metachronous (80.49%). Out of 41 patients, 25 (60.98%) were females and 16 (39.02%) were males. The most common sites of primary tumor were head and neck cancers that have followed by gynecological cancers, breast cancer, lung cancer, esophageal cancer, and then the others. Among the second malignancy, the most common site was breast and gastrointestinal tract that have followed by lung and gynecological cancers. Out of the total number of cases with double location, 14 tumors (34.15%) have belonged to the breast, out of which 5 (12.20%) have represented first locations and 7 (17.07%) have been second locations. Both locations have belonged to the breast in 2 patients (4.9%). In 5 cases (12.20%), there were associations of breast-cervix and in 6 cases (14.63%), there were association of lung-head & neck cancers.
The incidence of multiple primary malignancies has not been rare at all. Screening procedures have especially been useful for the early detection of associated tumors, whereas careful monitoring of patients has treated for primary cancer, and then a good communication between patients and medical care team would certify not only an early detection for secondary tumors, but only finally & subsequently, an appropriate management.
已诊断患有癌症的患者,根据各种遗传、环境和医源性风险因素,有患另一种新发恶性肿瘤的终生风险。癌症患者由于治疗方式得当可能存活更长时间,进而可能发生新的异时性恶性肿瘤。本文旨在报告我们观察到的癌症患者中同时性和异时性第二原发性恶性肿瘤患病率上升的趋势,并回顾相关文献。
对诊断为新发第二恶性肿瘤的患者进行基于医院的前瞻性数据回顾性收集。该研究在2009年至2012年的4年期间进行。所有根据沃伦和盖茨标准经组织学证实为第二恶性肿瘤的患者均被纳入。记录了有关部位、就诊年龄、性别、同时性或异时性、治疗等各种细节。
在观察到的41例多原发性恶性肿瘤病例中,8例为同时性(19.51%),33例为异时性(80.49%)。41例患者中,25例(60.98%)为女性,16例(39.02%)为男性。原发性肿瘤最常见的部位是头颈癌,其次是妇科癌症、乳腺癌、肺癌、食管癌,然后是其他癌症。在第二恶性肿瘤中,最常见的部位是乳腺和胃肠道,其次是肺癌和妇科癌症。在双部位病例总数中,14个肿瘤(34.15%)属于乳腺,其中5个(12.20%)为第一部位,7个(17.07%)为第二部位。2例患者(4.9%)两个部位均为乳腺。5例(12.20%)存在乳腺-子宫颈关联,6例(14.63%)存在肺-头颈癌关联。
多原发性恶性肿瘤的发病率一点也不罕见。筛查程序对于相关肿瘤的早期检测特别有用,而对原发性癌症患者进行仔细监测,并且患者与医疗团队之间进行良好沟通,不仅可以确保继发性肿瘤的早期检测,而且最终及随后还能进行适当的管理。